Literature DB >> 16385626

Role of DC-SIGN in the activation of dendritic cells by HPV-16 L1 virus-like particle vaccine.

Alfonso J García-Piñeres1, Allan Hildesheim, Matthew Trivett, Marcus Williams, Li Wu, Vineet N Kewalramani, Ligia A Pinto.   

Abstract

Dendritic cell-specific intercellular adhesion molecule-grabbing non-integrin (DC-SIGN), a specific C-type lectin expressed on DC, binds and transmits different pathogens to susceptible cells. In the present study, we examined the role of DC-SIGN in the capture of human papillomavirus (HPV) pseudovirions and activation of DC. We demonstrate that HPV virus-like particles (VLP) bind to DC-SIGN expressed on transfected Raji cells and that antibodies against DC-SIGN block this interaction. DC take up VLP, which activate expression of costimulatory markers and cytokines/chemokines. Although our results indicate that DC-SIGN is not the major receptor for VLP in DC, this interaction contributes to the activation of DC surface antigens (HLA class I) and of various cytokines/chemokines, particularly TNF-alpha, IL-6, and RANTES. Induction of these markers in DC by VLP was significantly abrogated when binding to DC-SIGN was blocked by anti-DC-SIGN antibodies. These results suggest that DC-SIGN has a functional role in DC activation induced by HPV-16 L1-VLP, and thus highlight new aspects of DC interactions with HPV VLP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16385626     DOI: 10.1002/eji.200535068

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

Authors:  L Buonaguro; M L Tornesello; M Tagliamonte; R C Gallo; L X Wang; R Kamin-Lewis; S Abdelwahab; G K Lewis; F M Buonaguro
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27.

Authors:  J Mohamad Fakruddin; Richard A Lempicki; Robert J Gorelick; Jun Yang; Joseph W Adelsberger; Alfonso J Garcia-Pineres; Ligia A Pinto; H Clifford Lane; Tomozumi Imamichi
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

3.  Bovine papillomavirus type 1 infection is mediated by SNARE syntaxin 18.

Authors:  Valerie Laniosz; Kha C Nguyen; Patricio I Meneses
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

Review 4.  Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.

Authors:  Sanjay Swaminathan; Lue Dai; H Clifford Lane; Tomozumi Imamichi
Journal:  Cytokine Growth Factor Rev       Date:  2013-08-17       Impact factor: 7.638

5.  Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.

Authors:  Alfonso García-Piñeres; Allan Hildesheim; Lori Dodd; Troy J Kemp; Marcus Williams; Clayton Harro; Douglas R Lowy; John T Schiller; Ligia A Pinto
Journal:  Clin Vaccine Immunol       Date:  2007-06-27

Review 6.  Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.

Authors:  Jesús Zepeda-Cervantes; Josué Orlando Ramírez-Jarquín; Luis Vaca
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

Review 7.  Dendritic Cells/Macrophages-Targeting Feature of Ebola Glycoprotein and its Potential as Immunological Facilitator for Antiviral Vaccine Approach.

Authors:  Titus Abiola Olukitibi; Zhujun Ao; Mona Mahmoudi; Gary A Kobinger; Xiaojian Yao
Journal:  Microorganisms       Date:  2019-09-29

Review 8.  Influence of dendritic cells on viral pathogenicity.

Authors:  Giulia Freer; Donatella Matteucci
Journal:  PLoS Pathog       Date:  2009-07-31       Impact factor: 6.823

Review 9.  The C type lectins DC-SIGN and L-SIGN: receptors for viral glycoproteins.

Authors:  Pierre-Yves Lozach; Laura Burleigh; Isabelle Staropoli; Ali Amara
Journal:  Methods Mol Biol       Date:  2007
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.